Ventilatory effects of almitrine bismesylate in congenital central hypoventilation syndrome.
Patients with congenital central hypoventilation syndrome (CCHS) lack hypercapnic and hypoxic stimulation of ventilation but have demonstrated carotid body function in response to hyperoxia and to pharmacological stimulation with doxapram. This study investigated the ventilatory effects of almitrine bismesylate, a carotid body stimulant, in 12 patients with CCHS. Measurements of minute ventilation, tidal volume (VT), respiratory rate (RR) and transcutaneous PO2 (TCPO2) were taken before and after administration of 4.5 mg/kg and 6 mg/kg of almitrine. Twenty-four hour pharmacokinetic studies were performed in 7 patients who received 4.5 mg/kg and in 6 patients who received 6 mg/kg almitrine. There was no significant improvement in ventilatory and gas exchange parameters at either dose of almitrine despite appropriate peak serum concentration of the drug at the time of the studies. These results suggest that almitrine is not a useful ventilatory stimulant in children with CCHS.
D015765:Almitrine; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D009994:Osmolar Concentration; D010879:Piperazines / Q000097:blood / Q000627:therapeutic use*; D012119:Respiration / Q000187:drug effects*; D012891:Sleep Apnea Syndromes / Q000151:congenital* / Q000188:drug therapy
D010879:Piperazines; D015765:Almitrine